Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update of ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis completed, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-06-25